Verteporfin photodynamic therapy in the age of antiangiogenic therapy

Photodynamic therapy with verteporfin was the first approved pharmacological treatment for choroidal neovascularization in patients with age-related macular degeneration, pathologic myopia and ocular histoplasmosis syndrome. With the introduction of anti-VEGF therapy, verteporfin photodynamic therapy is no longer the first line of treatment for neovascular age-related macular degeneration. Ongoing clinical trials will determine the future role of PDT alone or as part of a more individualized combination therapy.